Abstract:To study the clinical characteristics, risk factors and therapeutic outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia (Ph(+)aALL).The clinical data of 117 newly diagnosed adults with Ph(+)ALL in our hospital between January 1995 and December 2009 were retrospectively analyzed. And their prognoses were followed up.There were 117(16.1%) of 727 aALL patients diagnosed as Ph(+)aALL. Among the 117 cases, 64.1% patients were classified as pre-B immunophenotype and 31.3% as common B immunophenotype, 37.5% patients with co-expression of myeloid antigens (CD13 or CD33), and 98.4% patients with positive CD34. The complete remission (CR) rate after 1 or 2 cycles of induction chemotherapy was 62.2% in Ph(+)aALL group versus 82% in Ph(-)aALL group (P = 0.000). The median disease-free survival time of Ph(+) group was 6 months and the median survival time was 9 months. Sole karyotype abnormality subgroup t(9;22) accounted for 53% of all Ph(+)aALL patients and additional karyotype abnormality subgroup, t(9;22) plus other chromosome variation, accounted for 47%. Patients in sole karyotype abnormality subgroup had slightly lower CR rate (59.6% vs 62.5%, P = 0.768), longer median survival time (7 months vs 4 months, P = 0.158), and higher 3-year overall survival rate (27.3% vs 14.4%, P = 0.271). For the myeloid antigen co-expressed patients and the only lymphocytic antigen expressed ones, CR rate was 56.0% and 61.5% (P = 0.750), the median survival time was 5 months and 4 months (P = 0.182), and the 3-year overall survival rate was 16.0% and 15.0% (P = 0.354), respectively. In the imatinib plus combination chemotherapy treatment group, 81.3% patients achieved CR, compared with that of 58.3% in patients treated with only traditional combination chemotherapy (P = 0.083). The median survival time was 9.5 months and 6 months (P = 0.003) in these two subgroup, and 3-year overall survival rate was 52.2% and 10.3% (P = 0.029), respectively. For the patients receiving allo-HSCT after CR and that receiving traditional consolidation chemotherapy, the median survival time was 15 months and 6 months (P = 0.000), and the 3-year overall survival rate was 62.0% and 10.3% (P = 0.000), respectively. For the patients receiving imatinib as consolidation-maintenance treatment and that receiving allo-HSCT, the median survival time was 12 months and 15 months (P = 0.300), and the 3-year overall survival rate was 64.7% and 62% (P = 0.505), respectively.Of all adult ALL patients, the Ph(+) subgroup accounted for about 16.1%, which have unfavorable prognosis such as lower CR rate and shorter survival duration under traditional chemotherapy. Neither additional chromosome abnormalities to t(9;22) nor co-expression of myeloid antigen had negative effect on CR rate and survival duration. Addition of imatinib to the therapy was beneficial to improve the CR rate and survival duration. Either receiving imatinib as consolidation-maintenance treatment or allo-HSCT after complete remission can improve long-term survival rate of Ph(+) adult ALL group significantly.

Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients

Blastic transformation in chronic myelogenous leukemia: experience with 50 patients

Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia]

Extramedullary blast crisis of CD 34 + CD 38-leukemia stem cells in chronic myeloid leukemia resistant to tyrosine kinase inhibitors : a report of two cases

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Characteristics and Outcome of Chromosomal Abnormalities in Ph Negative Cells of Chronic Myelogenous Leukemia Patients Treated with Tyrosine Kinase Inhibitors

The morphological, immunophenotypical and cytogenetic characteristics study of blast crisis in chronic myeloid leukemia]

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia

[Clinical and Laboratory Characteristics of 12 Ph/BCR-ABL Positive Acute Myeloid Leukemia Patients].

Chronic Myeloid Leukemia Unveils Its Dark Side: A Rare Case of Megakaryocytic Blast Crisis

Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN

Chromosome and Bcr Rearrangement in Chronic Myelogenous Leukaemia and Their Correlation with Clinical States and Prognosis of the Disease

Prognostic Factors and Clinical Outcomes in Patients with Blast Phase Chronic Myeloid Leukemia

[Efficacy of Imatinib Mesylate, a Specific Inhibitor of BCR/ABL Tyrosine Kinase, on Chronic Myeloid Leukemia in Blast Phase].

[The Efficacy of Imatinib Mesylate for 124 Patients with Chronic Myeloid Leukemia in Accelerated and Blastic Phase].

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/RUNX1::RUNX1T1: Selecting Optimal Treatment Based on Clinical and Molecular Findings

Immunophenotypic and Cytogenetic Characteristics of the Blast Crisis in Chronic Myeloid Leukemia

Clinical Characteristics and Outcomes of Adults with Philadelphia Chromosome Positive And/or Bcr-Abl Positive Acute Lymphoblastic Leukemia: a Single Center Study from China.